While Dyne Therapeutics Inc has overperformed by 7.01%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DYN fell by -15.75%, with highs and lows ranging from $26.22 to $6.36, whereas the simple moving average jumped by 47.74% in the last 200 days.
On December 10, 2025, Oppenheimer Upgraded Dyne Therapeutics Inc (NASDAQ: DYN) to Outperform. A report published by Oppenheimer on October 10, 2025, Downgraded its rating to ‘Perform’ for DYN. Raymond James also Upgraded DYN shares as ‘Strong Buy’, setting a target price of $35 on the company’s shares in a report dated August 25, 2025. Bernstein Initiated an Mkt Perform rating on June 24, 2025, and assigned a price target of $13. Raymond James initiated its ‘Outperform’ rating for DYN, as published in its report on June 11, 2025. Oppenheimer’s report from June 02, 2025 suggests a price prediction of $34 for DYN shares, giving the stock a ‘Outperform’ rating. Evercore ISI also rated the stock as ‘Outperform’.
Analysis of Dyne Therapeutics Inc (DYN)
One of the most important indicators of Dyne Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -60.66% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 13.47, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and DYN is recording 3.02M average volume. On a monthly basis, the volatility of the stock is set at 7.14%, whereas on a weekly basis, it is put at 5.28%, with a gain of 3.01% over the past seven days. Furthermore, long-term investors anticipate a median target price of $39.19, showing growth from the present price of $19.85, which can serve as yet another indication of whether DYN is worth investing in or should be passed over.
How Do You Analyze Dyne Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 26.51%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 73.77% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
DYN shares are owned by institutional investors to the tune of 73.77% at present.
